HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect

Duplex-immunoassay of ovarian cancer biomarker CA125 and HE4 based carbon dot decorated dendritic mesoporous silica nanoparticles

Fluorescent lateral flow immunoassay (FLFIA) is widely used mainly because of its low cost and instant detection. Its limit of detection (LOD) is closely related to fluorescence signals, and the development of fluorescence signals with fine performance remains a challenge. In this work, dendritic mesoporous silica nanoparticles (DMSNs) were used as fine carriers due to their large pore size and stable performance. We successfully synthesized carbon dots (CDs) with a 560 nm maximum emission wavelength (CD₅₆₀) by the hydrothermal method. A new type of fluorescence signal for FLFIA was observed by loading CD₅₆₀ on DMSNs through the Si-O bond which is denoted as DMSNs@CD₅₆₀. Applying DMSNs@CD₅₆₀ to the FLFIA can eliminate the influence of interfacial background blue fluorescence thus improving its detection sensitivity. The formed DMSNs@CD₅₆₀-FLFIA achieved high sensitivity detection of ovarian cancer biomarkers carbohydrate antigen 125 (CA125) and human epididymal protein 4 (HE4). The LOD of CA125 is 0.5 U mL^-1 and the correlation coefficient R² = 0.985, and the LOD of HE4 reaches 0.05 ng mL^-1 and the correlation coefficient R² = 0.981. The DMSNs@CD₅₆₀-FLFIA is sensitive and efficient providing a new method for the early diagnosis of ovarian cancer.

High-Density Gold Nanoparticles Implanted on Mg/Fe LDH Nanoflowers Assisted Lateral Flow Immuno-Dipstick Assay for Visual Detection of Human Epididymal Protein 4

The timelier and more accurate the diagnosis of the disease, the higher the patient’s survival rate. Human epididymal protein 4 (HE4) has great significance as a biomarker of concern for reflecting ovarian cancer. Herein, we prepared a novel optical label that can be used in lateral-flow immuno-dipstick assay (LFIA) for sensitive visual detection of HE4 by implanting hydrophobic gold nanoparticles (Au NPs) at high density in Mg/Fe LDH nanoflowers (MF NFs). MF NFs with large specific surface area, high porosity, abundant active binding sites, and stable structure were employed for the first time as templates to directly anchor Au NPs in the organic phase. After simple modification with an optimized amount of branched polyethyleneimine, not only could MF@Au NFs be dispersed in the aqueous phase, but also amino functional groups were introduced on its surface to facilitate subsequent antibody coupling steps. The limit of detection reaches 50 pM with a detection range of 50 to 1000 pM. This work initially explored how MF NFs can be used to load signal labels with ideal stability and signal amplification capabilities, which greatly improves the practicability of LFIA and highlights its important role in the field of rapid diagnostics.

Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial Ovarian Cancer Through the p38 MAPK Pathway

INTRODUCTION

Ovarian cancer has a high mortality rate due to difficulties in early detection and chemotherapy resistance. Human epididymal protein 4 (HE4) has been adopted as a novel serum biomarker for early ovarian cancer diagnosis, and the presence of Lewis y antigen modifications on HE4 in ovarian cancer cell lines has been detected in previous studies. The aim of this study was to analyze the expression of HE4 and Lewis y antigen in human ovarian cancer in order to find a correlation between them, as well as with the clinical pathological parameters of patients with ovarian cancer.

METHODS

Immunohistochemistry was used to detect the respective expression of these compounds in two patient groups (chemotherapy-resistant and chemotherapy-sensitive) containing a total of 95 patients. Then, a bioinformatic approach was adopted and online large sample databases (TCGA, CCLE, and GTEx; Metascape, Cytoscape) were used to explore the potential mechanisms of action of these compounds.

RESULTS

The results of this study demonstrate that high HE4 and Lewis y expression could be used as markers for chemotherapy resistance and poor prognosis in patients with ovarian cancer. These two expression events were widely correlated in various cancer tissues and are thought to act by activating the p38 mitogen-activated protein kinases (MAPK) pathway and inducing Vascular Endothelial Growth Factor A (VEGFA), Prostaglandin-Endoperoxide Synthase 2 (PTGS2), Early Growth Response 1 (EGR1), and Hypoxia-Inducible Factor 1-Alpha (HIFI1A), thereby promoting malignant biological behavior and resistance in ovarian cancer.

CONCLUSIONS

These findings not only reveal the possible mechanism by which HE4 and Lewis y antigen affect ovarian cancer but also identify a four-gene signature that could be very useful in ovarian cancer detection and/or the development of new targeted therapies.

Detection of carcinoma in serous effusions: a review

A malignant serous effusion is one of the most common complications of advanced tumors, indicating a poor prognosis and having a profound impact on diagnosis, treatment, and prognosis. It is of great significance to identify benign and malignant effusions quickly and accurately. Both cellular and non-cellular components in the effusion can be employed for detection, diagnostic methods are necessary to obtain a definite diagnosis and more relevant information such as tumor classification. In this review, we focus on the comparison of several widespread cytological preparation methods, enrichment technology of exfoliated cells, and present tests for serous effusions, mainly including routine and special stains, immunocytochemistry, electron microscopy, enzyme-linked immunosorbent assay, flow cytometry, and molecular analysis.

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies

Background

This study explored the value of ascites and serum CA125, CEA, and CA19-9 levels and ascites DNA ploidy analysis for the diagnosis of peritoneal carcinomatosis (PC) in patients with gastrointestinal and ovarian malignancies, which can cause ascites and may disseminate peritoneally.

Methods

We measured ascites and serum levels of CA125, CEA, CA19-9 and performed an ascites DNA ploidy analysis in 58 patients with PC and 44 patients without PC.

Results

We found that a high expression level of CA125 in ascites fluid was associated with the occurrence of PC in patients with gastrointestinal and ovarian malignancies (P<0.001), and that high CEA and CA19- 9 levels in ascites fluid were associated with PC in patients with gastrointestinal malignancies (P=0.001, P=0.002). But, these tumor marker expression levels in ascites fluid were not significantly associated with the PC stage (P>0.05). We found similar serum levels of CA125, CEA, and CA19-9 between patients with gastrointestinal and ovarian malignancies and PC and those without PC (P>0.05). We found that the presence of three or more cells with heteroploid in the ascites samples was significantly associated with PC in gastrointestinal and ovarian malignancies (P<0.001). In addition, the best ROC curves and highest AUCs were achieved by combining the CA125 level and heteroploid cell analysis results (AUC for gastrointestinal and ovarian malignancies, 0.815, AUC for gastrointestinal malignancies, 0.873). Moreover, the combined ascites CA125 level and result of heteroploid cell analysis provided the best diagnostic sensitivity and specificity for PC (75.9% and 79.5%, respectively, in gastrointestinal and ovarian malignancies; 85.0% and 86.7%, respectively, in gastrointestinal malignancies).

Conclusion

Ascites levels of CA125, CEA, CA19-9, and heteroploid cells can be considered valuable markers for the diagnosis of PC in patients with gastrointestinal and ovarian cancer.